Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Jared Ryan Kelly purchased 50,400 shares of Oncolytics Biotech stock in a transaction dated Wednesday, July 16th. The stock was acquired at an average price of C$1.63 per share, with a total value of C$82,284.50.
Oncolytics Biotech Stock Down 2.8%
ONC traded down C$0.05 during trading on Friday, hitting C$1.73. The stock had a trading volume of 245,934 shares, compared to its average volume of 147,357. The stock has a 50 day simple moving average of C$0.90 and a two-hundred day simple moving average of C$0.95. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. Oncolytics Biotech Inc. has a twelve month low of C$0.44 and a twelve month high of C$2.08. The company has a market capitalization of C$133.34 million, a PE ratio of -4.82 and a beta of 1.35.
Analyst Ratings Changes
Separately, Jones Trading downgraded Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
View Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
